Compound Library
Evidence-based research summaries across 9 categories.
Long-acting GHRH analogue with Drug Affinity Complex (DAC) modification. Creates sustained GH pulse elevation through extended half-life via albumin binding.
Highly selective GH secretagogue and GHRP. Studied for its selective stimulation of GH without significant cortisol or prolactin elevation — considered the "cleanest" GHRP in research.
Combined CJC-1295/Ipamorelin studied for synergistic GH axis stimulation via dual-pathway mechanism — GHRH + GHRP synergy documented in literature.
First 29 amino acids of endogenous GHRH. FDA-approved (now withdrawn) GHRH analogue; most studied GH secretagogue with the longest clinical history.
Stabilized GHRH analogue (trans-3-hexenoic acid modification). FDA-approved for HIV-associated lipodystrophy. Extensively studied in multiple human RCTs.
Hexapeptide GH secretagogue. Early GHRP with potent GH-releasing activity; also stimulates ghrelin (orexigenic) pathways, driving appetite increase as a notable research finding.
Recombinant human growth hormone (somatropin). Most studied peptide hormone with decades of clinical trial data across multiple indications.
C-terminal fragment of HGH. Studied for isolated lipolytic activity, separating fat-burning effects from growth-promoting and anti-insulin effects of full HGH.
Long-acting IGF-1 analogue with arginine substitution and glutamate extension for reduced binding protein affinity. Higher bioavailability than native IGF-1.
Second-generation GH-releasing hexapeptide. More potent GH pulse amplitude than GHRP-6 with less ghrelin-mediated appetite stimulation. Studied for GH deficiency, body composition, and anti-aging hormone optimization.
Potent synthetic hexapeptide GH secretagogue — among the most potent GHS-R1a agonists. Studied for cardiac repair beyond GH axis effects via direct CD36 receptor activity. Orphan drug potential for growth hormone deficiency.
Orally active non-peptide GH secretagogue. Only oral GHS-R1a agonist compound in widespread research. Sustained IGF-1 elevation with once-daily oral dosing makes it uniquely convenient in the GH secretagogue class.
Stabilized 29-amino acid GHRH analogue without the DAC modification of CJC-1295. Shorter acting than CJC-1295-DAC — produces physiological-style GH pulses. Often combined with GHRP-2 or ipamorelin for synergistic GH release.
GHRH analogue without the Drug Affinity Complex (DAC) modification. Functionally identical to Modified GRF(1-29). Short-acting GHRH analogue favored by researchers who prefer pulsatile GH release over the sustained "GH bleed" of the DAC version.